Nothing Special   »   [go: up one dir, main page]

CL2022003453A1 - Compuestos de imidazopiridazina con actividad como inhibidores de alk2. - Google Patents

Compuestos de imidazopiridazina con actividad como inhibidores de alk2.

Info

Publication number
CL2022003453A1
CL2022003453A1 CL2022003453A CL2022003453A CL2022003453A1 CL 2022003453 A1 CL2022003453 A1 CL 2022003453A1 CL 2022003453 A CL2022003453 A CL 2022003453A CL 2022003453 A CL2022003453 A CL 2022003453A CL 2022003453 A1 CL2022003453 A1 CL 2022003453A1
Authority
CL
Chile
Prior art keywords
compounds
activity
imidazopyridazine compounds
alk2
alk2 inhibitors
Prior art date
Application number
CL2022003453A
Other languages
English (en)
Inventor
Jun Pan
Liangxing Wu
Wenqing Yao
Yu Bai
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2022003453A1 publication Critical patent/CL2022003453A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)

Abstract

Se describen compuestos de Fórmula (I), métodos de uso de los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, tales como el cáncer.
CL2022003453A 2020-06-12 2022-12-06 Compuestos de imidazopiridazina con actividad como inhibidores de alk2. CL2022003453A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12

Publications (1)

Publication Number Publication Date
CL2022003453A1 true CL2022003453A1 (es) 2023-05-26

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003453A CL2022003453A1 (es) 2020-06-12 2022-12-06 Compuestos de imidazopiridazina con actividad como inhibidores de alk2.

Country Status (17)

Country Link
US (2) US11840546B2 (es)
EP (1) EP4165051A1 (es)
JP (1) JP2023530088A (es)
KR (1) KR20230025434A (es)
CN (1) CN115956081A (es)
AR (1) AR122587A1 (es)
AU (1) AU2021288107A1 (es)
BR (1) BR112022025191A2 (es)
CA (1) CA3184811A1 (es)
CL (1) CL2022003453A1 (es)
CO (1) CO2022017969A2 (es)
EC (1) ECSP22093652A (es)
IL (1) IL298248A (es)
MX (1) MX2022015493A (es)
PE (1) PE20230491A1 (es)
TW (1) TW202214660A (es)
WO (1) WO2021252781A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019401649A1 (en) 2018-12-20 2021-07-08 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL202623B1 (pl) 2000-06-28 2009-07-31 Smithkline Beecham Plc Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna
EA201000123A1 (ru) * 2007-07-26 2010-08-30 Новартис Аг Органические соединения
MX2010004244A (es) 2007-10-17 2010-04-30 Novartis Ag Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk).
US8987273B2 (en) 2010-07-28 2015-03-24 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-B]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CN103649093B (zh) 2011-05-06 2017-07-07 拜耳知识产权有限责任公司 取代的咪唑并吡啶和咪唑并哒嗪及其用途
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SI3377488T1 (sl) 2015-11-19 2022-11-30 Incyte Corporation Heterociklične spojine kot imunomodulatorji
EP3390361B1 (en) 2015-12-17 2022-03-16 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
EP3828171A1 (en) 2015-12-22 2021-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190218214A1 (en) 2016-09-14 2019-07-18 Vanderbilt University Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
WO2018053136A1 (en) 2016-09-15 2018-03-22 Armstrong World Industries, Inc. Ceiling system with air movement
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzoxazole derivatives as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3558990T3 (da) 2016-12-22 2022-09-12 Incyte Corp Tetrahydroimidazo[4,5-c]pyridinderivater som pd-l1 internaliseringsinducere
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3570843A1 (en) * 2017-01-18 2019-11-27 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
AU2019401649A1 (en) * 2018-12-20 2021-07-08 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Also Published As

Publication number Publication date
EP4165051A1 (en) 2023-04-19
IL298248A (en) 2023-01-01
PE20230491A1 (es) 2023-03-23
CO2022017969A2 (es) 2023-02-27
TW202214660A (zh) 2022-04-16
WO2021252781A1 (en) 2021-12-16
AU2021288107A1 (en) 2022-12-15
ECSP22093652A (es) 2023-02-28
AR122587A1 (es) 2022-09-21
US20240083918A1 (en) 2024-03-14
JP2023530088A (ja) 2023-07-13
CA3184811A1 (en) 2021-12-16
KR20230025434A (ko) 2023-02-21
CN115956081A (zh) 2023-04-11
US20210388003A1 (en) 2021-12-16
MX2022015493A (es) 2023-03-21
BR112022025191A2 (pt) 2023-03-07
US11840546B2 (en) 2023-12-12

Similar Documents

Publication Publication Date Title
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
ECSP24009853A (es) Compuestos tricíclicos como inhibidores de kras
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2022001671A1 (es) Inhibidores de sos1
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
BR112021018303A2 (pt) Novos inibidores de pequenas moléculas de fatores de transcrição tead
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
ECSP088573A (es) Triazolopiridazinas como moduladores de tirosina cinasa
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
CL2022000457A1 (es) Triazolopirimidinas como inhibidores de a2a/a2b.
GT201000172A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
CO2022000481A2 (es) Inhibidores de enzimas
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
UY39574A (es) Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
CL2023000061A1 (es) Macrociclos y su uso
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
CO2023008475A2 (es) Inhibidores de enzimas
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
CO2024009582A2 (es) Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap/taz tead
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos
BR112021019589A2 (pt) Derivados de isocromenos como inibidores de fosfoinositídeo 3-cinases